Journal of Biomedical Science

, Volume 6, Issue 1, pp 53–63 | Cite as

Peptide loading in the endoplasmic reticulum accelerates trafficking of peptide: MHC class II complexes in B cells

  • Stanislaw Morkowski
  • Graça Raposo
  • Hans J. Geuze
  • Alexander Y. Rudensky
Original Paper


In a combination of biochemical and immunoelectron-microscopical approaches we studied intracellular trafficking and localization of the endoplasmic-reticulum (ER)-formed complexes of murine MHC class II molecule I-Ab and an antigenic peptide Eα52–68 covalently linked to its β-chain. The association with the peptide in the ER leads to sharp acceleration of the intracellular trafficking of the complexes to the plasma membrane. Within the cells, Eα52–68:I-Ab complexes accumulate in the multivesicular MHC class II compartment (MIIC), but not in denser multilaminar or intermediate type MIICs. The changes in the trafficking of ER-formed complexes result solely from the presence of the tethered peptide, since wild-type class II molecules traffic similarly in bare lymphocyte syndrome cells and in wild-type antigen-presenting cells.

Key Words

MHC class II Invariant chain Class II:peptide complexes Intracellular trafficking 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Amigorena S, Drake JR, Webster P, Mellman I. Transient accumulation of new class II MHC molecules in a novel endocytic compartment in B lymphocytes. Nature 369:113–118;1994.CrossRefPubMedGoogle Scholar
  2. 2.
    Anderson KS, Cresswell P. A role for calnexin (IP90) in the assembly of class II MHC molecules. EMBO J 13:675–682;1994.PubMedGoogle Scholar
  3. 3.
    Avva RR, Cresswell P. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity 1:763–774;1994.CrossRefPubMedGoogle Scholar
  4. 4.
    Bartido SM, Diment S, Reiss CS. Processing of a viral glycoprotein in the endoplasmic reticulum for class II presentation. Eur J Immunol 25:2211–2219;1995.PubMedGoogle Scholar
  5. 5.
    Bijlmakers ME, Benaroch P, Ploegh HL. Mapping functional regions in the lumenal domain of the class II-associated invariant chain. J Exp Med 180:623–629;1994.CrossRefPubMedGoogle Scholar
  6. 6.
    Bikoff EK, Huang L-Y, Episkopou V, Meerwijk J, Germain RN, Robertson EJ. Defective major histocompatibility complex class II assembly, transport, peptide acquisition and CD4+ T cell selection in mice lacking invariant chain expression. J Exp Med 177:1699–1712;1993.CrossRefPubMedGoogle Scholar
  7. 7.
    Bonnerot C, Marks MS, Cosson P, Robertson EJ, Bikoff EK, Germain RN, Bonifacino JS. Association with BiP and aggregation of class II MHC molecules synthesized in the absence of invariant chain. EMBO J 13:934–944;1994.PubMedGoogle Scholar
  8. 8.
    Busch R, Cloutier I, Sekaly R-P, Hammerling GJ. Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum. EMBO J 15:418–430;1996.PubMedGoogle Scholar
  9. 9.
    Castellino F, Germain RN. Extensive trafficking of MHC class II-invariant chain complexes in the endocytic pathway, appearance of peptide-loaded class II in multiple compartments. Immunity 2:73–86;1995.CrossRefPubMedGoogle Scholar
  10. 10.
    Chicz RM, Urban RG, Gorga JC, Stern LJ, Vignali DA, Strominger JL. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 358:764–766;1992.CrossRefPubMedGoogle Scholar
  11. 11.
    Cresswell P. Intracellular class II HLA-antigens are accessible to transferrin-neuraminidase conjugates internalized by receptor-mediated endocytosis. Proc Natl Acad Sci USA 82:81–85;1985.Google Scholar
  12. 12.
    Cresswell P. Invariant chain structure and MHC class II function. Cell 84:505–507;1996.CrossRefPubMedGoogle Scholar
  13. 13.
    Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II αβ dimers and facilitates peptide loading. Cell 83:155–165;1995.CrossRefGoogle Scholar
  14. 14.
    Eastman S, Deftos M, DeRoos P, Hsu DH, Teyton L, Braunstein NS, Hackett CJ, Rudensky AY. A study of the assembly of invariant chain peptide:MHC class II complexes using a new complex-specific monoclonal antibody. Eur J Immunol 26:385–393;1995.Google Scholar
  15. 15.
    Elliott EA, Drake JR, Amigorena S, Elsemore J, Webster P, Mellman I, Flavell RA. The invariant chain is required for intracellular transport and function of major histocompatibility complex class II molecules. J Exp Med 179:681–694;1994.CrossRefPubMedGoogle Scholar
  16. 16.
    Freisenwinkel IM, Schenck K, Koch N. The segment of invariant chain that is critical for association with major histocompatibility complex class II molecules contains the sequence of a peptide eluted from class II polypeptides. Proc Natl Acad Sci USA 90:9703–9706;1993.PubMedGoogle Scholar
  17. 17.
    Germain RN, Rinker AGJ. Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules. Nature 363:725–728;1993.CrossRefPubMedGoogle Scholar
  18. 18.
    Ghosh P, Amaya M, Mellins E, Wiley DC. The structure of an intermediate in class II MHC maturation:CLIP bound to HLA-DR3. Nature 378:457–462;1995.CrossRefPubMedGoogle Scholar
  19. 19.
    Hume CR, Shookster LA, Collins N, O'Reilly R, Lee JS. Bare lymphocyte syndrome: Altered HLA class II expression in B cell lines derived from two patients. Hum Immunol 25:1–11;1989.CrossRefPubMedGoogle Scholar
  20. 20.
    Hunt DF, Michel H, Dickinson TA, Shabanowitz J, Cox AL, Sakaguchi K, Apella E, Grey HM, Sette A. Peptides presented to the immune system by the murine class II major histocompatibility molecule I-Ad. Science 256:1817–1820;1992.PubMedGoogle Scholar
  21. 21.
    Ignatowicz L, Winslow G, Bill J, Kappler J, Marrack P. Cell surface expression of class II MHC proteins bound by a single peptide. J Immunol 154:3852–3862;1995.PubMedGoogle Scholar
  22. 22.
    Ignatowicz L, Kappler J, Marrack P. The repertoire of T cells shaped by a single MHC/peptide ligand. Cell 84:521–529;1996.CrossRefPubMedGoogle Scholar
  23. 23.
    Kleijmeer MJ, Raposo G, Geuze HJ. Characterization of MHC class II compartments by immunoelectron microscopy. Methods Enzymol 10:191–207;1996.CrossRefGoogle Scholar
  24. 24.
    Kovats S, Drover S, Marshall WH, Freed D, Whiteley PE, Nepom GT, Blum JS. Coordinate effects in human histocompatibility leukocyte antigen class II expression and antigen presentation in bare lymphocyte syndrome. J Exp Med 179:2017–2022;1994.CrossRefPubMedGoogle Scholar
  25. 25.
    Kovats S, Grubin CE, Eastman S, DeRoos P, Dongre A, Van Kaer L, Rudensky AY. Invariant chain-independent function of the H2-M in the formation of endogenous peptide-major histocompatibility complex class II complexes in vivo. J Exp Med 187:245–251;1998.CrossRefPubMedGoogle Scholar
  26. 26.
    Kozono H, White J, Clements J, Marrack P, Kappler J. Production of soluble MHC class II proteins with covalently bound single peptides. Nature 369:151–154;1994.Google Scholar
  27. 27.
    Liou W, Geuze HJ, Slot JW. Improving structural integrity of cryosections for immunogold labeling. Histochem Cell Biol 106:41–58;1996.CrossRefPubMedGoogle Scholar
  28. 28.
    Maric MA, Taylor MD, Blum JS. Endosomal aspartic proteinases are required for invariantchain processing. Proc Natl Acad Sci USA 91:2171–2175;1994.PubMedGoogle Scholar
  29. 29.
    Mellins E, Cameron P, Amaya M, Goodman S, Pious D, Smith L, Arp B. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides. J Exp Med 179:541–549;1994.CrossRefPubMedGoogle Scholar
  30. 30.
    Morkowski S, Goldrath AW, Eastman S, Ramachandra L, Freed DC, Whiteley P, Rudensky AY. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates. J Exp Med 182:1403–1413;1995.CrossRefPubMedGoogle Scholar
  31. 31.
    Morkowski S, Raposo G, Kleijmeer MJ, Geuze HJ, Rudensky AY. Assembly of an abundant endogenous MHC class II: Peptide complex in MHC class II compartments. Eur J Immunol 27:609–617;1997.PubMedGoogle Scholar
  32. 32.
    Peters PJ, Neefjes JJ, Oorschot V, Ploegh HL, Geuze HJ. Segregation of MHC class II molecules from MHC class I molecules in the Golgi complex for transport to lysosomal compartments. Nature 349:656–669;1991.CrossRefGoogle Scholar
  33. 33.
    Pinet V, Vergelli M, Martin R, Bakke O, Long EO. Antigen presentation mediated by recycling of surface HLA-DR molecules. Nature 375:603–606;1995.CrossRefPubMedGoogle Scholar
  34. 34.
    Ramachandra L, Kovats S, Rudensky AY. Variation in HLA-DM expression in influences conversion of MHC class αβ: Class II associated invariant chain peptide complexes to mature peptide-bound class II αβ dimers in a normal B cell line. J Immunol 156:2196–2204;1996.PubMedGoogle Scholar
  35. 35.
    Raposo G, Nijman HW, Stoorvogel W, Leijendekker R, Harding CV, Melief CJM, Geuze HJ. B lymphocytes secrete antigen-presenting vesicles. J Exp Med 183:1161–1171;1996.CrossRefPubMedGoogle Scholar
  36. 36.
    Riberdy JM, Cresswell P. The antigen-processing mutant T2 suggests a role for MHC-linked genes in class II antigen processing. J Immunol 148:2586–2590;1992.PubMedGoogle Scholar
  37. 37.
    Roche PA, Teletski CL, Stang E, Bakke O, Long EO. Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization. Proc Natl Acad Sci USA 90:8581–8586;1993.PubMedGoogle Scholar
  38. 38.
    Romagnoli P, Germain RN. The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport and peptide occupancy. J Exp Med 180:1107–1113;1994.CrossRefPubMedGoogle Scholar
  39. 39.
    Rudensky AY, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CA Jr. Sequence analysis of peptides bound to MHC class II molecules. Nature 353:622–628;1991.CrossRefPubMedGoogle Scholar
  40. 40.
    Rudensky AY, Maric M, Eastman S, Shoemaker L, DeRoos P, Blum JS. Intracellular assembly and transport of endogenous peptide: MHC class II complexes. Immunity 1:585–594;1994.CrossRefPubMedGoogle Scholar
  41. 41.
    Sette A, Ceman S, Kubo RT, Sakaguchi K, Apella E, Hunt DF, Davis TA, Michel H, Shabanowitz J, Rudersdorf R, Grey HM, DeMars R. Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant. Science 258:1801–1804;1992.PubMedGoogle Scholar
  42. 42.
    Sloan S, Camerson P, Porter G, Gammon M, Amaya M, Mellins E, Zaller DM. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 375:802–806;1995.CrossRefPubMedGoogle Scholar
  43. 43.
    Slot JW, Geuze HJ, Gigengack S, Lienhard GE, James DE. Immuno-localization of the insulin regulatable glucose transporter in brown adipose tissue of the rat. J Cell Biol 113:123–135;1991.CrossRefPubMedGoogle Scholar
  44. 44.
    Slusarewicz P, Hui N, Warren G. Purification of rat liver Golgi stacks. In: Celis JE, ed. Cell Biology. A Laboratory Handbook. New York, Academic Press, 509–516;1994.Google Scholar
  45. 45.
    Viville S, Neefjes J, Lotteau V, Dierich A, Lemeur M, Ploegh H, Benoist C, Mathis D. Mice lacking the MHC class II-associated invariant chain. Cell 72:635–648;1993.CrossRefPubMedGoogle Scholar
  46. 46.
    Zhong G, Castellino F, Romagnoli P, Germain RN. Evidence that binding site occupancy is necessary and sufficient for effective MHC class II transport through the secretory pathway redefines the primary function of class II-associated invariant chain peptides (CLIP). J Exp Med 184:2061–2072;1996.CrossRefPubMedGoogle Scholar

Copyright information

© National Science Council 1999

Authors and Affiliations

  • Stanislaw Morkowski
    • 1
  • Graça Raposo
    • 2
  • Hans J. Geuze
    • 2
  • Alexander Y. Rudensky
    • 3
    • 1
  1. 1.The Department of ImmunologyUniversity of Washington School of MedicineSeattleUSA
  2. 2.Department of Cell Biology and Institute of BiomembranesUniversity of Utrecht School of MedicineUtrechtThe Netherlands
  3. 3.Howard Hughes Medical InstituteUniversity of WashingtonSeattleUSA

Personalised recommendations